Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Tolvaptan is a vasopressin V(2)-receptor antagonist that has shown promise in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). Tolvaptan was, however, associated with liver injury in some ADPKD patients. Inhibition of bile acid transporters may be contributing factors to drug-induced liver injury. In this study, the ability of tolvaptan and two metabolites, DM-4103 and DM-4107, to inhibit human hepatic transporters (NTCP, BSEP, MRP2, MRP3, and MRP4) and bile acid transport in sandwich-cultured human hepatocytes (SCHH) was explored. IC(50) values were determined for tolvaptan, DM-4103 and DM-4107 inhibition of NTCP (∼41.5, 16.3, and 95.6 μM, respectively), BSEP (31.6, 4.15, and 119 μM, respectively), MRP2 (>50, ∼51.0, and >200 μM, respectively), MRP3 (>50, ∼44.6, and 61.2 μM, respectively), and MRP4 (>50, 4.26, and 37.9 μM, respectively). At the therapeutic dose of tolvaptan (90 mg), DM-4103 exhibited a C(max)/IC(50) value >0.1 for NTCP, BSEP, MRP2, MRP3, and MRP4. Tolvaptan accumulation in SCHH was extensive and not sodium-dependent; intracellular concentrations were ∼500 μM after a 10-min incubation duration with tolvaptan (15 μM). The biliary clearance of taurocholic acid (TCA) decreased by 43% when SCHH were co-incubated with tolvaptan (15 μM) and TCA (2.5 μM). When tolvaptan (15 μM) was co-incubated with 2.5 μM of chenodeoxycholic acid, taurochenodeoxycholic acid, or glycochenodeoxycholic acid in separate studies, the cellular accumulation of these bile acids increased by 1.30-, 1.68-, and 2.16-fold, respectively. Based on these data, inhibition of hepatic bile acid transport may be one of the biological mechanisms underlying tolvaptan-associated liver injury in patients with ADPKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering that mechanisms leading to alterations in bile-acid homeostasis are believed in part to be responsible for recent prominent late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017)”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Slizgi et al. 2016
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879 · cited 2×
“The best-fit model was assessed based on visual inspection of the observed versus predicted data and the Akaike Information Criteria (Akaike, 1974).”
MethodTolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215 · cited 1×
“…available benzazepine derivative, is a selective vasopressin V2-receptor antagonist (Yamamura et al., 1998) used in the treatment of clinically significant hyponatremia (Schrier et al., 2006), volume overload in heart failure (Fukunami et al., 2011) and liver cirrhosis with edema (Sakaida, 2014).”
BackgroundBile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics
Hofmann, A. F., & Hagey, L. R. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7568-6 · Cited by 859
Bile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
Enterohepatic bile salt transporters in normal physiology and liver disease
Kullak-ublick, G. A., Stieger, B., & Meier, P. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.06.005 · Cited by 658
Tamai, I., Nezu, J.-I., Uchino, H., Sai, Y., Oku, A., Shimane, M., & Tsuji, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2922 · Cited by 642
Meier, P. J., & Stieger, B. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.082201.100300 · Cited by 586
Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6
Cui, Y., König, J., Leier, I., Buchholz, U., & Keppler, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004968200 · Cited by 515
Research works printed but not linked: 2
- Phillips M. J. Poucell S. Patterson J. Valencia P. (1987). Cholestasis. In The Liver: An Atlas and Text of Ultrastructural Pathology ( Phillips M. J. Poucell S. Patterson J. Valencia P. , Eds.), pp. 101–158. Raven Press, New York.
- Qualyst Transporter Solutions Technical Application Bulletin TAB Biol 005. (2011). TAB Biol 005v2.
Cited by
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“…late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017), there is an increasing need and awareness to better…”
BackgroundRenal Drug Transporters and Drug Interactions
Ivanyuk, A., Livio, F., Biollaz, J., & Buclin, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0506-8 · Cited by 221
Kenna, J. G., Taskar, K. S., Battista, C., Bourdet, D. L., Brouwer, K. L. R., Brouwer, K. R., Dai, D., Funk, C., Hafey, M. J., Lai, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1222 · Cited by 123
Self-citationWoodhead, J. L., Brock, W. J., Roth, S. E., Shoaf, S. E., Brouwer, K. L. R., Church, R. J., Grammatopoulos, T. N., Stiles, L., Siler, S. Q., Howell, B. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw193 · Cited by 96
“Previous research had assessed the potential of tolvaptan, DM-4103, and DM-4107 to inhibit the bile acid transporters BSEP and NTCP (Slizgi et al., 2016).”
InfluentialSelf-citationDrug rechallenge following drug-induced liver injury
Hunt, C. M., Papay, J. I., Stanulovic, V., & Regev, A. (2017) · Hepatology · doi:10.1002/hep.29152 · Cited by 72
“These two compounds are associated with immunoallergic injury (with HLA marker carriage substantively increasing risk of lapatinib liver injury), mitochondrial impairment,(35, 56) and BSEP inhibition.(37, 57) Tolvaptan is a vasopressin V2-receptor antagonist indicated for hyponatremia and evaluated for autosomal domin…”
Metadata
- Authors
- Slizgi, J. R., Lu, Y., Brouwer, K. R., St. Claire, R. L., Freeman, K. M., Pan, M., Brock, W. J., & Brouwer, K. L. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Otsuka Pharmaceutical Development & Commercialization, Inc. (United States) (US)
- Corresponding author
- Brouwer, Kim L. R.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10-26
- Volume
- 149
- Issue
- 1
- Pages
- 237-250
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- PMC
- PMC6169477
- OpenAlex
- W2273286870
- Cited by
- 53
- References
- 78
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 5
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Toxicological Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- American Association of Pharmaceutical Scientists
- Otsuka Pharmaceutical
- Otsuka Pharmaceutical Development and Commercialization
- National Institute of General Medical Sciences (R01GM041935)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- tolvaptan, drug-induced liver injury, bile acid transporters, normal tissue complication probability, bile salt export pump, MRP2, MRP3, MRP4, autosomal dominant polycystic kidney disease, hepatotoxicity, taurocholate, chenodeoxycholic acid, biliary excretion
- MeSH terms
- Tolvaptan, Multidrug Resistance-Associated Protein 2, Animals, Benzazepines, Carrier Proteins, Cricetulus, Humans, Membrane Glycoproteins, Taurocholic Acid, CHO Cells, Polycystic Kidney, Autosomal Dominant, Hepatocytes, ATP-Binding Cassette, Sub-Family C Proteins, Chemical and Drug Induced Liver Injury, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.